Page last updated: 2024-12-05

propoxycaine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Propoxycaine: A local anesthetic of the ester type that has a rapid onset of action and a longer duration of action than procaine hydrochloride. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1017) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6843
CHEMBL ID1195
CHEBI ID8496
SCHEMBL ID83073
MeSH IDM0017767

Synonyms (53)

Synonym
BRD-K18250272-003-03-7
4-amino-2-propoxybenzoic acid, 2-(diethylamino)ethyl ester
benzoic acid, 4-amino-2-propoxy-, 2-(diethylamino)ethyl ester
ranocaine
brn 2382110
propoxycaine [inn]
win 3459-2
2'-diethylaminoethyl 2-propoxy-4-aminobenzoate
propoxicainum
propoxycainum [inn-latin]
propoxicaina [inn-spanish]
pravocaine
einecs 201-670-9
2-diethylaminoethyl 4-amino-2-propoxybenzoate
propossicaina [dcit]
blockain
2-diethylaminoethyl 4-amino-2-propoxybenzoic acid ester
BSPBIO_001018
PRESTWICK3_001059
PRESTWICK2_001059
BPBIO1_001120
AB00514714
C07895
86-43-1
propoxycaine
SPBIO_002939
PRESTWICK1_001059
PRESTWICK0_001059
NCGC00016505-02
CHEMBL1195
chebi:8496 ,
unii-epd1eh7f53
propossicaina
propoxycainum
propoxicaina
epd1eh7f53 ,
2-(diethylamino)ethyl 4-amino-2-propoxybenzoate
SCHEMBL83073
propoxycaine [who-dd]
DTXSID6047866
NCGC00016505-04
CAJIGINSTLKQMM-UHFFFAOYSA-N
2-(diethylamino)ethyl 4-amino-2-propoxy-benzoate
AB00514714_06
DB09342
J-506353
mfcd00864426
bdbm50225492
Q7250421
NCGC00016505-06
2-(diethylamino)ethyl4-amino-2-propoxybenzoate
SB82647
EN300-18562918

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The penetration of sulforhodamine B (SRB) into the two corneas of a freshly killed mouse was measured after one eye was briefly exposed to a solution of a possibly toxic substance."( A permeability test for acute corneal toxicity.
Maurice, D; Singh, T, 1986
)
0.27
"A drug registry was established at Southern California College of Optometry (SCCO) to study use rates and incidence of adverse side effects of the nine pharmaceutical agents in the California optometry law."( Use of diagnostic pharmaceutical agents and incidence of adverse effects.
Applebaum, M; Jaanus, SD, 1983
)
0.27
" Synthetic local anesthetics such as tetracaine and proparacaine were developed which were more potent and less toxic than cocaine, but still produced corneal epithelium defects if used chronically."( Comparative toxicity of tetracaine, proparacaine and cocaine evaluated with primary cultures of rabbit corneal epithelial cells.
Acosta, D; Grant, RL, 1994
)
0.29
" Proparacaine was statistically more toxic than were the others."( Corneal endothelial toxicity of topical anesthesia.
Judge, AJ; Lee, DA; Miller, KM; Najafi, K, 1997
)
0.3
"Both tetracaine and proparacaine had toxic effects on stromal keratocytes related not only to drug concentrations but also to time exposure."( Toxicity of topical anesthetic agents to human keratocytes in vivo.
Kasetsuwan, N; LaBree, L; McDonnell, PJ; Moreira, LB; Sanchez, D; Shah, SS, 1999
)
0.3
" All six studies demonstrated that a short course of dilute topical anesthetic provided efficacious analgesia without adverse effects or delayed epithelial healing."( The Safety of Topical Anesthetics in the Treatment of Corneal Abrasions: A Review.
Milne, K; Otterness, K; Rezaie, S; Swaminathan, A, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" The greater bioavailability achieved by this vehicle allows much lower drug concentrations to be used, reducing the likelihood of systemic adverse reactions."( A comparison of the efficacy and duration of action of topically applied proxymetacaine using a novel ophthalmic delivery system versus eye drops in healthy young volunteers.
Barnard, NA; Burns, JM; Edgar, DF; Geraint, M; Gudgeon, AC; Lawrenson, JG, 1993
)
0.29
" Such host-guest complexes were investigated in view of their potential use as new therapeutic formulations, designed to increase the bioavailability and/or to decrease the systemic toxicity of proparacaine in anesthesia procedures."( Proparacaine complexation with beta-cyclodextrin and p-sulfonic acid calix[6]arene, as evaluated by varied (1)H-NMR approaches.
Arantes, LM; de Paula, E; Fernandes, SA; Marsaioli, AJ; Scarelli, C, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
"A simple and rapid spectrophotometric procedure has been developed for the determination of four local anaesthetics containing a free primary amine moiety and of procainamide hydrochloride as the drug substances and in dosage forms."( Use of 7,7,8,8-tetracyanoquinodimethane for spectrophotometric determination of certain local anaesthetics and procainamide hydrochloride.
Hassan, HY; Hussein, SA; Mohamed, AM; Mohamed, HA, 1991
)
0.28
" After rats were injected intrathecally with proxymetacaine, oxybuprocaine, bupivacaine, and lidocane, dose-response curves were constructed."( Intrathecal oxybuprocaine and proxymetacaine produced potent and long-lasting spinal anesthesia in rats.
Chen, YC; Chen, YW; Chu, CC; Hung, CH; Wang, JJ, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency16.93300.01237.983543.2770AID1645841
cytochrome P450 2D6Homo sapiens (human)Potency3.37860.00108.379861.1304AID1645840
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency1.99530.00207.533739.8107AID891
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency0.35480.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency0.00040.891312.067628.1838AID1487
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1061889Displacement of [3H]BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes after 60 mins by scintillation counting2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
A highly predictive 3D-QSAR model for binding to the voltage-gated sodium channel: design of potent new ligands.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1472421Half life in human plasma at 1 uM by HPLC-MS/MS analysis2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (260)

TimeframeStudies, This Drug (%)All Drugs %
pre-199068 (26.15)18.7374
1990's58 (22.31)18.2507
2000's54 (20.77)29.6817
2010's66 (25.38)24.3611
2020's14 (5.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.08 (24.57)
Research Supply Index5.83 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials58 (20.64%)5.53%
Reviews9 (3.20%)6.00%
Case Studies23 (8.19%)4.05%
Observational1 (0.36%)0.25%
Other190 (67.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Single-Masked, Active-Controlled, Parallel-Group Evaluation of Safety and the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution (AG-920) in a Pediatric Population [NCT05325853]Phase 361 participants (Actual)Interventional2022-04-06Completed
Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections [NCT01027611]Phase 3120 participants (Actual)Interventional2009-10-31Completed
Efficacy and Safety of Anesthetic Impregnated Bandage Soft Contact Lens (BSCL) in Pain Management After Photorefractive Keratectomy (PRK). [NCT04283331]Phase 430 participants (Anticipated)Interventional2020-06-01Recruiting
[NCT03049163]30 participants (Anticipated)Interventional2016-10-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT05325853 (2) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT05325853 (2) [back to overview]The Proportion of Participants in Which an Eye Exam Was Able to be Performed

Number of Participants With Treatment Emergent Adverse Events (TEAEs)

TEAEs will be summarized by treatment group using frequency and percent for each system, organ, class (SOC) and preferred term within each SOC. Summaries will be presented separately for ocular and non-ocular Adverse Events (AEs). (NCT05325853)
Timeframe: From randomization through study completion (up to 4 days following treatment)

InterventionParticipants (Count of Participants)
AG-9200
Proparacaine0

[back to top]

The Proportion of Participants in Which an Eye Exam Was Able to be Performed

Was the investigator was able to perform the eye examination without additional anesthesia (NCT05325853)
Timeframe: Two to four minutes following treatment (last drop) of IMP

InterventionParticipants (Count of Participants)
AG-92030
Proparacaine30

[back to top]